(ERAS) Erasca - Ratings and Ratios
Naporafenib, ERAS-0015, ERAS-4001, ERAS-12, ERAS-801, ERAS-007, ERAS-601
Description: ERAS Erasca
Erasca Inc (NASDAQ:ERAS) is a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers. The companys pipeline includes several promising candidates, including naporafenib, ERAS-0015, ERAS-4001, ERAS-12, ERAS-801, ERAS-007, and ERAS-601, targeting various types of solid tumors and glioblastoma.
Key pipeline assets include naporafenib, currently in a pivotal Phase 3 trial (SEACRAFT-2) for NRAS-mutated melanoma, and ERAS-801, a CNS-penetrant EGFR inhibitor in Phase 1 trials for EGFR-altered recurrent glioblastoma. The companys diverse portfolio and strategic partnerships with Novartis, Katmai Pharmaceuticals, and NiKang Therapeutics demonstrate its commitment to advancing oncology treatments.
From a financial perspective, Erascas market capitalization stands at approximately $408 million, with a negative P/E ratio due to the companys current loss-making status. The return on equity (ROE) is -36.56%, indicating significant investment in research and development. Key performance indicators (KPIs) to monitor include the progress of naporafenib in its Phase 3 trial, the initiation of new clinical trials for other pipeline assets, and the companys cash burn rate, which will be crucial in determining its ability to fund future operations.
To evaluate Erascas potential, investors should closely watch the outcome of the SEACRAFT-2 trial, the companys ability to secure additional funding, and the competitive landscape of the oncology market. A thorough analysis of the companys financials, including its cash reserves and R&D expenses, will provide insights into its ability to execute on its pipeline and achieve future milestones.
ERAS Stock Overview
| Market Cap in USD | 440m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2021-07-16 |
ERAS Stock Ratings
| Growth Rating | -81.1% |
| Fundamental | 27.4% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -52.3% |
| Analyst Rating | 4.63 of 5 |
ERAS Dividends
Currently no dividends paidERAS Growth Ratios
| Growth Correlation 3m | 62.5% |
| Growth Correlation 12m | -68.1% |
| Growth Correlation 5y | -90.5% |
| CAGR 5y | -39.99% |
| CAGR/Max DD 3y | -0.46 |
| CAGR/Mean DD 3y | -0.57 |
| Sharpe Ratio 12m | -0.05 |
| Alpha | -55.68 |
| Beta | 0.218 |
| Volatility | 74.15% |
| Current Volume | 843.3k |
| Average Volume 20d | 768.8k |
| Stop Loss | 1.4 (-12.5%) |
| Signal | 0.50 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-128.3m TTM) > 0 and > 6% of Revenue (6% = 251.8k TTM) |
| FCFTA -0.25 (>2.0%) and ΔFCFTA -4.99pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 6733 % (prev 7045 %; Δ -312.2pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.22 (>3.0%) and CFO -99.1m > Net Income -128.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 11.04 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (283.4m) change vs 12m ago 62.62% (target <= -2.0% for YES) |
| Gross Margin -8.41% (prev 28.66%; Δ -37.07pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.86% (prev 1.06%; Δ -0.20pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -15.39
| (A) 0.63 = (Total Current Assets 310.7m - Total Current Liabilities 28.2m) / Total Assets 445.4m |
| (B) -1.87 = Retained Earnings (Balance) -832.5m / Total Assets 445.4m |
| warn (B) unusual magnitude: -1.87 — check mapping/units |
| (C) -0.23 = EBIT TTM -109.4m / Avg Total Assets 485.6m |
| (D) -11.38 = Book Value of Equity -832.1m / Total Liabilities 73.1m |
| Total Rating: -15.39 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 27.37
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -58.01% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.13 = 2.49 |
| 5. Debt/Ebitda -0.46 = -2.50 |
| 6. ROIC - WACC -33.34% = -12.50 |
| 7. RoE -31.19% = -2.50 |
| 8. Rev. Trend 17.81% = 0.89 |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend 59.61% = 1.49 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of ERAS shares?
Over the past week, the price has changed by +3.23%, over one month by -2.44%, over three months by +13.88% and over the past year by -43.26%.
Is Erasca a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ERAS is around 1.13 USD . This means that ERAS is currently overvalued and has a potential downside of -29.38%.
Is ERAS a buy, sell or hold?
- Strong Buy: 5
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ERAS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.6 | 185.6% |
| Analysts Target Price | 4.6 | 185.6% |
| ValueRay Target Price | 1.2 | -22.5% |
Last update: 2025-09-10 04:37
ERAS Fundamental Data Overview
CCE Cash And Equivalents = 300.7m USD (Cash And Short Term Investments, last quarter)
P/B = 1.185
Beta = 1.087
Revenue TTM = 4.20m USD
EBIT TTM = -109.4m USD
EBITDA TTM = -106.9m USD
Long Term Debt = 45.0m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 4.71m USD (from shortTermDebt, last quarter)
Debt = 49.7m USD (Calculated: Short Term 4.71m + Long Term 45.0m)
Net Debt = -16.7m USD (from netDebt column, last quarter)
Enterprise Value = 188.7m USD (439.7m + Debt 49.7m - CCE 300.7m)
Interest Coverage Ratio = unknown (Ebit TTM -109.4m / Interest Expense TTM 0.0)
FCF Yield = -58.01% (FCF TTM -109.5m / Enterprise Value 188.7m)
FCF Margin = -2609 % (FCF TTM -109.5m / Revenue TTM 4.20m)
Net Margin = -3057 % (Net Income TTM -128.3m / Revenue TTM 4.20m)
Gross Margin = -8.41% ((Revenue TTM 4.20m - Cost of Revenue TTM 4.55m) / Revenue TTM)
Tobins Q-Ratio = -0.23 (set to none) (Enterprise Value 188.7m / Book Value Of Equity -832.1m)
Interest Expense / Debt = 7.70% (Interest Expense 3.83m / Debt 49.7m)
Taxrate = 21.0% (US default)
NOPAT = -109.4m (EBIT -109.4m, no tax applied on loss)
Current Ratio = 11.04 (Total Current Assets 310.7m / Total Current Liabilities 28.2m)
Debt / Equity = 0.13 (Debt 49.7m / last Quarter total Stockholder Equity 372.3m)
Debt / EBITDA = -0.46 (Net Debt -16.7m / EBITDA -106.9m)
Debt / FCF = -0.45 (Debt 49.7m / FCF TTM -109.5m)
Total Stockholder Equity = 411.3m (last 4 quarters mean)
RoA = -28.80% (Net Income -128.3m, Total Assets 445.4m )
RoE = -31.19% (Net Income TTM -128.3m / Total Stockholder Equity 411.3m)
RoCE = -23.98% (Ebit -109.4m / (Equity 411.3m + L.T.Debt 45.0m))
RoIC = -26.60% (NOPAT -109.4m / Invested Capital 411.3m)
WACC = 6.75% (E(439.7m)/V(489.4m) * Re(6.82%)) + (D(49.7m)/V(489.4m) * Rd(7.70%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 10.27%
Discount Rate = 6.82% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -109.5m)
Revenue Correlation: 17.81 | Revenue CAGR: 0.0%
Rev Growth-of-Growth: -913.3
EPS Correlation: 59.61 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 25.76
Additional Sources for ERAS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle